Abstract
Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within three hours of the onset of stroke.
Keywords
MedicineTissue plasminogen activatorRecombinant tissue plasminogen activatorIntracerebral hemorrhageStroke (engine)Ischemic strokeClinical trialRandomized controlled trialT-plasminogen activatorBrain ischemiaInternal medicineAcute strokeFibrinolytic agentIschemiaCardiologySurgerySubarachnoid hemorrhageModified Rankin Scale
Affiliated Institutions
Related Publications
A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: <u>T</u>h<u>R</u>omb<u>E</u>ctomy <u>A</u>nd <u>t</u>PA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration
Rationale Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical devices such as stent retrievers are now showing overwhelming effica...
Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke
Background and Purpose We sought to identify variables associated with intracerebral hemorrhage in patients with acute ischemic stroke who receive tissue plasminogen activator (...
Intra-arterial Prourokinase for Acute Ischemic Stroke
Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusi...
The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)
Background and Purpose —The Thrombolytic Therapy in Acute Ischemic Stroke Study, which started in August of 1991, was designed to assess the efficacy and safety of intravenous r...
Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke
Background and Purpose— The National Institutes of Health (NIH) estimates that stroke costs now exceed $45 billion per year. Stroke is the third leading cause of death and one o...
Publication Info
- Year
- 1995
- Type
- article
- Volume
- 333
- Issue
- 24
- Pages
- 1581-1588
- Citations
- 11503
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
11503
OpenAlex
Cite This
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
(1995).
Tissue Plasminogen Activator for Acute Ischemic Stroke.
New England Journal of Medicine
, 333
(24)
, 1581-1588.
https://doi.org/10.1056/nejm199512143332401
Identifiers
- DOI
- 10.1056/nejm199512143332401